# Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy

> **NCT04276337** · — · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 50 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Chemotherapy Effect
- Circulating Tumor DNA

## Interventions

- **DIAGNOSTIC_TEST:** LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)

## Key facts

- **NCT ID:** NCT04276337
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2020-04-30
- **Final completion:** 2023-08-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04276337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04276337, "Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04276337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*